# Next Generation Sequencing-Based Stratification of Front Line Treatment of HighGrade Neuroendocrine Carcinoma

> **NCT04452292** · NA · COMPLETED · sponsor: **Charles Kunos** · enrollment: 2 (actual)

## Conditions studied

- Large-Cell Neuroendocrine Carcinoma

## Interventions

- **OTHER:** Treatment Specific for Non-Small Cell Carcinoma/Adenocarcinoma
- **OTHER:** Treatment for Small Cell Lung Cancer

## Key facts

- **NCT ID:** NCT04452292
- **Lead sponsor:** Charles Kunos
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-09-14
- **Primary completion:** 2022-05-04
- **Final completion:** 2023-03-14
- **Target enrollment:** 2 (ACTUAL)
- **Last updated:** 2023-05-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04452292

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04452292, "Next Generation Sequencing-Based Stratification of Front Line Treatment of HighGrade Neuroendocrine Carcinoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04452292. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*